Reviewing the current treatment approaches for bullous pemphigoid – analysis of literature
DOI:
https://doi.org/10.12775/JEHS.2025.78.57666Keywords
Bullous pemphigoid, autoimmune blistering disease, corticosteroids therapyAbstract
Bullous pemphigoid (BP) is an autoimmune blistering disorder primarily affecting the elderly, particularly older men, and is characterized by type 2 inflammation. The disease is defined by autoantibodies targeting BP180 (BPAG2) and BP230 (BPAG1) within the basement membrane zone. Advanced age is a significant risk factor for BP, with additional associations identified, including certain medications—such as dipeptidyl peptidase-4 inhibitors and aldosterone antagonists—and neurological disorders like Parkinson’s disease.
The global annual cumulative incidence of BP is estimated at 8.2 cases per 1,000,000 individuals, with Europe reporting higher incidence rates than other regions. BP significantly impacts patients’ quality of life due to painful, pruritic skin lesions and is associated with a higher prevalence of psychiatric comorbidities, such as schizophrenia.
BP increases the risk of complications, including pulmonary embolism and pneumonia, and is linked to high mortality. These findings highlight the need for early diagnosis and comprehensive management to improve patient outcomes.
References
Werth VP, Murrell DF, Joly P, et al. Pathophysiology of Bullous Pemphigoid: Role of Type 2 Inflammation and Emerging Treatment Strategies (Narrative Review). Adv Ther. 2024;41(12):4418-4432.
https://doi.org/10.1007/s12325-024-02992-w
Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381(9863):320-332.
https://doi.org/10.1016/S0140-6736(12)61140-4
Yang W, Cai X, Zhang S, Han X, Ji L. Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: A systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2021;37(3):e3391.
https://doi.org/10.1002/dmrr.3391
Miida H, Fujiwara H, Ito M. Association between effective dose of prednisolone, alone or in conjunction with other immunosuppressants, and titre of anti-bullous pemphigoid 180 antibody: a retrospective study of 42 cases. Clin Exp Dermatol. 2011;36(5):485-488.
https://doi.org/10.1111/j.1365-2230.2010.04013.x
Liu SD, Chen WT, Chi CC. Association Between Medication Use and Bullous Pemphigoid: A Systematic Review and Meta-analysis. JAMA Dermatol. 2020;156(8):891-900.
https://doi.org/10.1001/jamadermatol.2020.1587
Zhou Q, Xiong Z, Yang D, Xiong C, Li X. The association between bullous pemphigoid and cognitive outcomes in middle-aged and older adults: A systematic review and meta-analysis. PLoS One. 2023;18(11):e0295135. Published 2023 Nov 30. https://doi.org/10.1371/journal.pone.0295135
Persson MSM, Begum N, Grainge MJ, Harman KE, Grindlay D, Gran S. The global incidence of bullous pemphigoid: a systematic review and meta-analysis. Br J Dermatol. 2022;186(3):414-425.
https://doi.org/10.1111/bjd.20743
Kouris A, Platsidaki E, Christodoulou C, et al. Quality of life, depression, anxiety and loneliness in patients with bullous pemphigoid. A case control study. An Bras Dermatol. 2016;91(5):601-603.
https://doi.org/10.1590/abd1806-4841.20164935
Huang IH, Wu PC, Liu CW, Huang YC. Association between bullous pemphigoid and psychiatric disorders: A systematic review and meta-analysis. J Dtsch Dermatol Ges. 2022;20(10):1305-1312.
https://doi.org/10.1111/ddg.14852
Joly P. Incidence of bullous pemphigoid and pemphigus vulgaris. BMJ. 2008;337(7662):a209. Published 2008 Jul 9.
https://doi.org/10.1136/bmj.a209
Chen X, Zhang Y, Luo Z, et al. Prognostic factors for mortality in bullous pemphigoid: A systematic review and meta-analysis. PLoS One. 2022;17(4):e0264705. Published 2022 Apr 15.
https://doi.org/10.1371/journal.pone.0264705
van Beek N, Schulze FS, Zillikens D, Schmidt E. IgE-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases. Expert Rev Clin Immunol. 2016;12(3):267-277.
https://doi.org/10.1586/1744666X.2016.1123092
Zhang L, Chen Z, Wang L, Luo X. Bullous pemphigoid: The role of type 2 inflammation in its pathogenesis and the prospect of targeted therapy. Front Immunol. 2023;14:1115083. Published 2023 Feb 16. https://doi.org/10.3389/fimmu.2023.1115083
Teraki Y, Hotta T, Shiohara T. Skin-homing interleukin-4 and -13-producing cells contribute to bullous pemphigoid: remission of disease is associated with increased frequency of interleukin-10-producing cells. J Invest Dermatol. 2001;117(5):1097-1102.
https://doi.org/10.1046/j.0022-202x.2001.01505.x
Borradori L, Van Beek N, Feliciani C, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2022;36(10):1689-1704.
https://doi.org/10.1111/jdv.18220
Dhaouadi T, Riahi A, Ben Abdallah T, Gorgi Y, Sfar I. Association of HLA class II alleles and haplotypes with bullous and mucus membrane pemphigoid risk: A systematic review, a meta-analysis and a meta-regression. Int J Immunopathol Pharmacol. 2024;38:3946320241296903.
https://doi.org/10.1177/03946320241296903
Chou PY, Yu CL, Wen CN, Tu YK, Chi CC. Bullous Pemphigoid Severity and Levels of Antibodies to BP180 and BP230: A Systematic Review and Meta-Analysis. JAMA Dermatol. 2024;160(11):1192-1200.
https://doi.org/10.1001/jamadermatol.2024.3425
Kirtschig G, Middleton P, Bennett C, Murrell DF, Wojnarowska F, Khumalo NP. Interventions for bullous pemphigoid. Cochrane Database Syst Rev. 2010;2010(10):CD002292. Published 2010 Oct 6.
https://doi.org/10.1002/14651858.CD002292.pub3
Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321-327.
https://doi.org/10.1056/NEJMoa011592
Venning VA, Taghipour K, Mohd Mustapa MF, Highet AS, Kirtschig G. British Association of Dermatologists' guidelines for the management of bullous pemphigoid 2012. Br J Dermatol. 2012;167(6):1200-1214.
https://doi.org/10.1111/bjd.12072
Nelson ML, Levy SB. The history of the tetracyclines. Ann N Y Acad Sci. 2011;1241:17-32.
https://doi.org/10.1111/j.1749-6632.2011.06354.x
Monk E, Shalita A, Siegel DM. Clinical applications of non-antimicrobial tetracyclines in dermatology. Pharmacol Res. 2011;63(2):130-145.
https://doi.org/10.1016/j.phrs.2010.10.007
Williams HC, Wojnarowska F, Kirtschig G, et al. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial [published correction appears in Lancet. 2017 Oct 28;390(10106):1948. doi: 10.1016/S0140-6736(17)32703-4]. Lancet. 2017;389(10079):1630-1638.
https://doi.org/10.1016/S0140-6736(17)30560-3
Chavez-Alvarez S, Herz-Ruelas M, Villarreal-Martinez A, Ocampo-Candiani J, Garza-Garza R, Gomez-Flores M. Azathioprine: its uses in dermatology. An Bras Dermatol. 2020;95(6):731-736.
https://doi.org/10.1016/j.abd.2020.05.003
Tirado-Sánchez A, Díaz-Molina V, Ponce-Olivera RM. Efficacy and safety of azathioprine and dapsone as an adjuvant in the treatment of bullous pemphigoid. Allergol Immunopathol (Madr). 2012;40(3):152-155.
https://doi.org/10.1016/j.aller.2010.12.009
Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol. 2007;143(12):1536-1542.
https://doi.org/10.1001/archderm.143.12.1536
Maksimovic V, Pavlovic-Popovic Z, Vukmirovic S, et al. Molecular mechanism of action and pharmacokinetic properties of methotrexate. Mol Biol Rep. 2020;47(6):4699-4708.
https://doi.org/10.1007/s11033-020-05481-9
Wojtczak M, Nolbrzak A, Woźniacka A, Żebrowska A. Can Methotrexate Be Employed as Monotherapy for Bullous Pemphigoid? Analysis of Efficiency and Tolerance of Methotrexate Treatment in Patients with Bullous Pemphigoid. J Clin Med. 2023;12(4):1638. Published 2023 Feb 18.
https://doi.org/10.3390/jcm12041638
Kjellman P, Eriksson H, Berg P. A retrospective analysis of patients with bullous pemphigoid treated with methotrexate. Arch Dermatol. 2008;144(5):612-616.
https://doi.org/10.1001/archderm.144.5.612
Gravani A, Gaitanis G, Spyridonos P, Alexis I, Tigas S, Bassukas ID. Methylprednisolone Plus Low-Dose Methotrexate for Bullous Pemphigoid-A Single Center Retrospective Analysis. J Clin Med. 2022;11(11):3193. Published 2022 Jun 2.
https://doi.org/10.3390/jcm11113193
Liang S, Cohen J, Soter N. The Use of Mycophenolate Mofetil in the Treatment of Bullous Pemphigoid. J Drugs Dermatol. 2022;21(2):151-155.
https://doi.org/10.36849/jdd.6042
Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol. 2007;143(12):1536-1542.
https://doi.org/10.1001/archderm.143.12.1536
Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol. 2001;45(3):420-434.
https://doi.org/10.1067/mjd.2001.114733
Murthy S, Schilf P, Patzelt S, et al. Dapsone Suppresses Disease in Preclinical Murine Models of Pemphigoid Diseases. J Invest Dermatol. 2021;141(11):2587-2595.e2.
https://doi.org/10.1016/j.jid.2021.04.009
Liddicoat AM, Lavelle EC. Modulation of innate immunity by cyclosporine A. Biochem Pharmacol. 2019;163:472-480.
https://doi.org/10.1016/j.bcp.2019.03.022
Boixeda JP, Soria C, Medina S, Ledo A. Bullous pemphigoid and psoriasis: treatment with cyclosporine. J Am Acad Dermatol. 1991;24(1):152.
https://doi.org/10.1016/s0190-9622(08)80058-8
Thivolet J, Barthelemy H, Rigot-Muller G, Bendelac A. Effects of cyclosporin on bullous pemphigoid and pemphigus. Lancet. 1985;1(8424):334-335.
https://doi.org/10.1016/s0140-6736(85)91099-2
Ujiie H, Arakawa M, Aoyama Y. Intravenous immunoglobulin in patients with bullous pemphigoid insufficient response to corticosteroids: Nationwide post-marketing surveillance in Japan. J Dermatol Sci. 2023;109(1):22-29.
https://doi.org/10.1016/j.jdermsci.2023.01.004
Banchereau J, Rousset F. Human B lymphocytes: phenotype, proliferation, and differentiation. Adv Immunol. 1992;52:125-262.
https://doi.org/10.1016/s0065-2776(08)60876-7
Polansky M, Eisenstadt R, DeGrazia T, Zhao X, Liu Y, Feldman R. Rituximab therapy in patients with bullous pemphigoid: A retrospective study of 20 patients. J Am Acad Dermatol. 2019;81(1):179-186.
https://doi.org/10.1016/j.jaad.2019.03.049
Tovanabutra N, Payne AS. Clinical outcome and safety of rituximab therapy for pemphigoid diseases. J Am Acad Dermatol. 2020;82(5):1237-1239.
https://doi.org/10.1016/j.jaad.2019.11.023
Seegräber M, Srour J, Walter A, Knop M, Wollenberg A. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol. 2018;11(5):467-474. https://doi.org/10.1080/17512433.2018.1449642
Huang D, Zhang Y, Yu Y, et al. Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study. Int Immunopharmacol. 2023;125(Pt A):111157.
https://doi.org/10.1016/j.intimp.2023.111157
Arasi S, Mennini M, Cafarotti A, Fiocchi A. Omalizumab as monotherapy for food allergy. Curr Opin Allergy Clin Immunol. 2021;21(3):286-291.
https://doi.org/10.1097/ACI.0000000000000744
Chebani R, Lombart F, Chaby G, et al. Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients [published correction appears in Br J Dermatol. 2024 Jun 20;191(1):e1. doi: 10.1093/bjd/ljae157]. Br J Dermatol. 2024;190(2):258-265.
https://doi.org/10.1093/bjd/ljad369
Le ST, Herbert S, Haughton R, et al. Rituximab and Omalizumab Combination Therapy for Bullous Pemphigoid. JAMA Dermatol. 2024;160(1):107-109. https://doi.org/10.1001/jamadermatol.2023.4508
Cao P, Xu W, Zhang L. Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review. Front Immunol. 2022;13:928621. Published 2022 Jun 13.
https://doi.org/10.3389/fimmu.2022.928621
Eskandarpour M, Chen YH, Nunn MA, Coupland SE, Weston-Davies W, Calder VL. Leukotriene B4 and Its Receptor in Experimental Autoimmune Uveitis and in Human Retinal Tissues: Clinical Severity and LTB4 Dependence of Retinal Th17 Cells. Am J Pathol. 2021;191(2):320-334.
https://doi.org/10.1016/j.ajpath.2020.10.010
Sadik CD, Rashid H, Hammers CM, et al. Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial. JAMA Dermatol. 2022;158(6):641-649.
https://doi.org/10.1001/jamadermatol.2022.1156
Passeron T, Fontas E, Boye T, Richard MA, Delaporte E, Dereure O. Treatment of Bullous Pemphigoid with Avdoralimab: Multicenter, Randomized, Open-Labeled Phase 2 Study. JID Innov. 2024;4(6):100307. Published 2024 Aug 23.
https://doi.org/10.1016/j.xjidi.2024.100307
Dhillon S. Sutimlimab: First Approval. Drugs. 2022;82(7):817-823. https://doi.org/10.1007/s40265-022-01711-5
Freire PC, Muñoz CH, Derhaschnig U, et al. Specific Inhibition of the Classical Complement Pathway Prevents C3 Deposition along the Dermal-Epidermal Junction in Bullous Pemphigoid. J Invest Dermatol. 2019;139(12):2417-2424.e2.
https://doi.org/10.1016/j.jid.2019.04.025
Markham A. Reslizumab: First Global Approval [published correction appears in Drugs. 2016 Jul;76(11):1159. doi: 10.1007/s40265-016-0608-x]. Drugs. 2016;76(8):907-911.
https://doi.org/10.1007/s40265-016-0583-2
Rhyou HI, Han SH, Nam YH. Successful induction treatment of bullous pemphigoid using reslizumab: a case report. Allergy Asthma Clin Immunol. 2021;17(1):117. Published 2021 Nov 16.
https://doi.org/10.1186/s13223-021-00619-1
Almezgagi M, Zhang Y, Hezam K, et al. Diacerein: Recent insight into pharmacological activities and molecular pathways. Biomed Pharmacother. 2020;131:110594.
https://doi.org/10.1016/j.biopha.2020.110594
Cho YT, Lee CH, Lee JY, Chu CY. Targeting antibody-mediated complement-independent mechanism in bullous pemphigoid with diacerein. J Dermatol Sci. 2024;114(1):44-51.
https://doi.org/10.1016/j.jdermsci.2024.03.001
Xue R, Li G, Zhou Y, et al. Efficacy and safety of low-dose interleukin 2 in the treatment of moderate-to-severe bullous pemphigoid: A single center perspective-controlled trial. J Am Acad Dermatol. 2024;91(6):1113-1117.
https://doi.org/10.1016/j.jaad.2024.08.033
Li Y, Liu X, Yu J, et al. Tofacitinib suppresses mast cell degranulation and attenuates experimental allergic conjunctivitis. Int Immunopharmacol. 2020;86:106737.
https://doi.org/10.1016/j.intimp.2020.106737
Oetjen LK, Mack MR, Feng J, et al. Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch. Cell. 2017;171(1):217-228.e13. https://doi.org/10.1016/j.cell.2017.08.006
Juczynska K, Wozniacka A, Waszczykowska E, et al. Expression of the JAK/STAT Signaling Pathway in Bullous Pemphigoid and Dermatitis Herpetiformis. Mediators Inflamm. 2017;2017:6716419.
https://doi.org/10.1155/2017/6716419
Fan B, Wang M. Tofacitinib in recalcitrant bullous pemphigoid: a report of seven cases. Br J Dermatol. 2023;188(3):432-434.
https://doi.org/10.1093/bjd/ljac078
Xiao Y, Xiang H, Li W. Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib. Dermatol Ther. 2022;35(10):e15754.
https://doi.org/10.1111/dth.15754
Winters JL. Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines. Hematology Am Soc Hematol Educ Program. 2012;2012:7-12.
https://doi.org/10.1182/asheducation-2012.1.7
Cui Y, Hu C, Cheng Y, Han X, Wang W. Plasmapheresis: a feasible choice for bullous pemphigoid patients infected with SARS-CoV-2. Int J Dermatol. 2022;61(2):252-256.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Julia Nowak, Agnieszka Najdek, Daria Oleksy, Dawid Komada, Urszula Kaczmarska, Aleksandra Woźniak, Michał Jakub Cioch, Marcin Mycyk, Kamil Hermanowicz, Katarzyna Doman
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 295
Number of citations: 0
